Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ribavirin ANDAs Await ICN Petition; FDA Generic Rule Takes Effect

Aug 18 2003

• By The Pink Sheet

Related Content

Citizen Petition Proposed Rule Withdrawn; FDA Cites Improved Response Rate

Apr 07 2003

Ribavirin ANDAs Await Decision By FDA; Par, Roche Expect Launch In August

Jul 28 2003

Generic Ribavirin Labels Will Carve Out Rebetol/PEG-Intron Indication

Jul 21 2003

Schering Rebetol Costs $1,650 Per Month, 3% Less Than Combo Rebetron

Oct 15 2001

Bristol Seeking Two NDAs For UFT Combos In Response To Rebetron Debate

Aug 30 1999

Waxman/Hatch Reform Should Await Pending Supreme Court Decision – Hatch

Apr 22 2002

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window